The company expects a significant contribution of income from this long -term agreement | Photo credit: Amit Dave
Divi laboratories said Friday that it has signed a supply agreement with a global firm of pharmaceutical products.
According to the long -term agreement, the company will manufacture and provide advanced intermediates according to the commercial terms agreed between the parties, Divi laboratories said in a regulatory presentation.
The company expects a significant contribution of the income of this long -term agreement, added without revealing the identity of the partner.
“The company is planning the addition of capacity in its manufacturing facilities with an estimated investment between ₹ 650 million rupees and ₹ 700 million rupees, which will be based on internal accumulations,” he said.
The company’s shares quoted 2.07 percent to ₹ 5,638,35 each in BSE.
Posted on April 18, 2025